Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

135
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
135
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

538
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
538

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of Myocardial Strain in Assessing Cardiac Masses: A Case Report.

Methodist DeBakey cardiovascular journal·2026
Same author

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in <i>LMNA</i>.

International journal of molecular sciences·2026
Same author

Genotype-phenotype heterogeneity among patients with lipodystrophy harboring rare POLD1 variants.

The Journal of clinical endocrinology and metabolism·2026
Same author

Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

International journal of molecular sciences·2026
Same author

Response to letter to the editor by Matsubara and colleagues.

Journal of clinical lipidology·2026
Same author

A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia.

The Journal of clinical investigation·2025

Related Experiment Video

Updated: Jun 7, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Complex dyslipidemia induced by lorlatinib therapy: A case study.

Julianna West1, Abhimanyu Garg2

  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA (Dr West).

Journal of Clinical Lipidology
|November 13, 2024
PubMed
Summary

Lorlatinib can cause complex hyperlipidemia in non-small cell lung cancer (NSCLC) patients. This side effect is unlikely due to nephrotic syndrome, as indicated by low urine protein levels.

Keywords:
HyperlipidemiaLDL cholesterolLorlatinibProteinuriaTriglycerides

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Related Experiment Videos

Last Updated: Jun 7, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Lorlatinib is an anaplastic lymphoma kinase (ALK) inhibitor for ALK-positive metastatic non-small cell lung cancer (NSCLC).
  • Hyperlipidemia is a known side effect of lorlatinib, but its mechanisms are unclear.
  • Nephrotic syndrome has been proposed as a cause for lorlatinib-induced hyperlipidemia.

Purpose of the Study:

  • To investigate the potential link between lorlatinib and hyperlipidemia.
  • To explore the underlying mechanisms of lorlatinib-induced dyslipidemia.
  • To assess the role of nephrotic syndrome in lorlatinib-associated hyperlipidemia.

Main Methods:

  • A case report of a 59-year-old female NSCLC patient treated with lorlatinib.
  • Monitoring of lipid levels (total cholesterol, triglycerides, LDL-C, HDL-C) during lorlatinib therapy.
  • Assessment of renal function via 24-hour urine protein excretion.

Main Results:

  • The patient experienced marked elevation in all measured lipid parameters after starting lorlatinib.
  • Aggressive lipid-lowering therapy with atorvastatin and ezetimibe was ineffective.
  • Urine protein excretion was minimal (226 mg/24h), ruling out nephrotic syndrome.

Conclusions:

  • Lorlatinib induced a complex dyslipidemia characterized by elevated LDL-C and HDL-C.
  • The mechanism of lorlatinib-induced hyperlipidemia remains undetermined.
  • Nephrotic syndrome is unlikely to be the cause of hyperlipidemia in many patients receiving lorlatinib.